486 related articles for article (PubMed ID: 15646065)
1. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
[TBL] [Abstract][Full Text] [Related]
2. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
[TBL] [Abstract][Full Text] [Related]
3. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
[TBL] [Abstract][Full Text] [Related]
4. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen.
Cabrera C; Marfil S; García E; Martinez-Picado J; Bonjoch A; Bofill M; Moreno S; Ribera E; Domingo P; Clotet B; Ruiz L
AIDS; 2006 Oct; 20(16):2075-80. PubMed ID: 17053353
[TBL] [Abstract][Full Text] [Related]
5. Resistance to enfuvirtide, the first HIV fusion inhibitor.
Greenberg ML; Cammack N
J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
[TBL] [Abstract][Full Text] [Related]
6. Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients.
Carmona R; Pérez-Alvarez L; Muñoz M; Casado G; Delgado E; Sierra M; Thomson M; Vega Y; Vázquez de Parga E; Contreras G; Medrano L; Nájera R
J Clin Virol; 2005 Mar; 32(3):248-53. PubMed ID: 15722032
[TBL] [Abstract][Full Text] [Related]
7. Virological fitness of HIV in patients with resistance to enfuvirtide.
Chibo D; Roth N; Roulet V; Skrabal K; Gooey M; Carolan L; Nicholls J; Papadakis A; Birch C
AIDS; 2007 Sep; 21(14):1974-7. PubMed ID: 17721108
[TBL] [Abstract][Full Text] [Related]
8. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
[TBL] [Abstract][Full Text] [Related]
9. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1.
Pérez-Alvarez L; Carmona R; Ocampo A; Asorey A; Miralles C; Pérez de Castro S; Pinilla M; Contreras G; Taboada JA; Nájera R
J Med Virol; 2006 Feb; 78(2):141-7. PubMed ID: 16372284
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy.
Poveda E; Rodés B; Lebel-Binay S; Faudon JL; Jimenez V; Soriano V
J Clin Virol; 2005 Dec; 34(4):295-301. PubMed ID: 16286053
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.
Poveda E; Briz V; Paraskevis D; Barreiro P; Hatzakis A; Soriano V
AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1078-82. PubMed ID: 17919101
[TBL] [Abstract][Full Text] [Related]
12. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
[TBL] [Abstract][Full Text] [Related]
13. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
[TBL] [Abstract][Full Text] [Related]
14. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.
Poveda E; Rodés B; Labernardière JL; Benito JM; Toro C; González-Lahoz J; Faudon JL; Clavel F; Schapiro J; Soriano V
J Med Virol; 2004 Sep; 74(1):21-8. PubMed ID: 15258964
[TBL] [Abstract][Full Text] [Related]
15. Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.
Loutfy MR; Raboud JM; Montaner JS; Antoniou T; Wynhoven B; Smaill F; Rouleau D; Gill J; Schlech W; Brumme ZL; Mo T; Gough K; Rachlis A; Harrigan PR; Walmsley SL
Antiviral Res; 2007 Jul; 75(1):58-63. PubMed ID: 17196268
[TBL] [Abstract][Full Text] [Related]
16. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.
Marcial M; Lu J; Deeks SG; Ziermann R; Kuritzkes DR
J Clin Microbiol; 2006 Sep; 44(9):3384-7. PubMed ID: 16954280
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.
Charpentier C; Jenabian MA; Piketty C; Karmochkine M; Tisserand P; Laureillard D; Bélec L; Si-Mohamed A; Weiss L
Scand J Infect Dis; 2011 May; 43(5):373-9. PubMed ID: 21341978
[TBL] [Abstract][Full Text] [Related]
18. Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes.
Covens K; Kabeya K; Schrooten Y; Dekeersmaeker N; Van Wijngaerden E; Vandamme AM; De Wit S; Van Laethem K
J Clin Virol; 2009 Apr; 44(4):325-8. PubMed ID: 19237313
[TBL] [Abstract][Full Text] [Related]
19. Enfuvirtide is active against HIV type 1 group O.
Poveda E; Barreiro P; Rodés B; Soriano V
AIDS Res Hum Retroviruses; 2005 Jun; 21(6):583-5. PubMed ID: 15989465
[TBL] [Abstract][Full Text] [Related]
20. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
Lalezari JP; Bellos NC; Sathasivam K; Richmond GJ; Cohen CJ; Myers RA; Henry DH; Raskino C; Melby T; Murchison H; Zhang Y; Spence R; Greenberg ML; Demasi RA; Miralles GD;
J Infect Dis; 2005 Apr; 191(7):1155-63. PubMed ID: 15747252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
